Phase 1 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You are 18 years of age or older.
• You have been diagnosed with an advanced or spreading solid tumour cancer, confirmed through a biopsy or cell sample test.
• Your cancer has a specific gene change called a KRAS mutation, or a gene variation called wild-type KRAS amplification, identified through an approved laboratory test.
• You have received between 1 and 4 previous cancer treatments, or you are unable to tolerate or are not suitable for other available treatments.
• Your cancer can be measured on scans using standard criteria (known as RECIST 1.1).
• You are reasonably well and able to carry out daily activities, with only minor limitations (this is measured on a standard scale called ECOG 0 or 1).
• You are willing to avoid becoming pregnant or fathering a child from the screening period until at least 90 days after your last dose of the study treatment.

Who may not be able to join:

• You have active cancer that has spread to the brain or the lining around the brain, unless you have already had treatment for brain metastases and meet certain recovery conditions (confirm with trial site).
• You have been diagnosed with another cancer within the past 2 years, unless it was fully treated with no signs of return, or it was a specific low-risk cancer type such as certain skin cancers, early-stage cervical, endometrial, bladder, prostate, or breast cancers (confirm with trial site).
• You still have unresolved side effects from previous cancer treatments.
• You are currently taking part in another clinical trial involving a treatment intervention.
• You have received chemotherapy, targeted therapy, or other cancer drugs too recently before starting this trial (specific waiting periods apply depending on the type of treatment — confirm with trial site).
• You have previously been treated with a type of drug called a KRAS/RAS degrader.
• You have had a significant heart problem within the 6 months before starting the study.
• You have an active infection that required antibiotics within 7 days before starting the study.
• You have HIV with a low immune cell count, a detectable level of virus in your blood, or are on certain HIV medications that may interfere with the study drug (confirm with trial site).
• You have a known history of drug-related liver damage, certain liver or bile duct conditions, or blockages in the bile ducts caused by stones or scarring (confirm with trial site).
• You have had major surgery within 4 weeks before starting the study, or you are still recovering from surgical complications.
• You have a known allergy or sensitivity to any of the ingredients in the study treatment.
• You have any condition that, in the doctor's opinion, would prevent you from fully understanding and agreeing to take part, or from following the study procedures.
• You are taking certain medications that strongly affect how the body processes drugs (specifically strong or moderate CYP3A4/5 inhibitors or inducers, or strong P-gp inhibitors or inducers) — this applies to the dose escalation part of the trial (confirm with trial site).
• Your blood tests show that your blood cell counts, liver function, or kidney function are not within acceptable levels (confirm with trial site).
• You have significant abnormalities in your heart's electrical activity shown on a resting heart trace (ECG).
• Your heart's electrical interval measurement (called QTcF) is 470 milliseconds or above on your ECG.
• You are a woman of childbearing age with a positive pregnancy test within 7 days of starting the study, or a confirmed ongoing pregnancy.
• You are currently breastfeeding or plan to breastfeed during the study or within 28 days after your last dose of the study drug.
• You have an active Hepatitis B infection (those with a past resolved infection or who are on stable antiviral treatment may still be eligible).
• You have an active Hepatitis C infection (those who have completed treatment and have confirmed clearance of the virus may still be eligible).

Important: Always verify eligibility with the trial site directly before applying.